Literature DB >> 810881

Free light chains of immunoglobulins in normal serum and urine determined by radioimmunoassay.

K Sölling.   

Abstract

A radioimmunoassay for determination of free light polypeptide chains from human immunoglobulins in serum and urine is described. The free light chains were isolated from the regular immunoglobulins by gel filtration on Sephadex G-100 columns. In the radioimmunoassay the free and antibody-bound 125I-labelled light chains were separated on gel filtration through Sephadex G-200 columns. The mean concentration of free light chains in serum from 20 normal subjects was 10.6 mg/1 for lambda chains and 13.2 mg/1 for kappa chains. The 24-hr urinary excretion was 1.1 mg for lambda chains and 3.2 mg for kappa chains.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810881

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  5 in total

1.  Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum.

Authors:  C R Tillyer; J Iqbal; J Raymond; M Gore; T J McIlwain
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

2.  Differences in kappa to lambda (kappa:lambda) ratios of serum and urinary free light chains.

Authors:  M Abe; T Goto; M Kosaka; D Wolfenbarger; D T Weiss; A Solomon
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Role of domain interactions in the aggregation of full-length immunoglobulin light chains.

Authors:  Enrico Rennella; Gareth J Morgan; Jeffery W Kelly; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-31       Impact factor: 11.205

4.  Free light chain synthesis by neoplastic cells in chronic lymphocytic leukaemia and non-Hodgkin's lymphoma.

Authors:  J Gordon; A R Howlett; J L Smith
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

5.  Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Authors:  C E Leurs; Ham Twaalfhoven; B I Lissenberg-Witte; V van Pesch; I Dujmovic; J Drulovic; M Castellazzi; T Bellini; M Pugliatti; J Kuhle; L M Villar; J C Alvarez-Cermeño; R Alvarez-Lafuente; H Hegen; F Deisenhammer; L M Walchhofer; E Thouvenot; M Comabella; X Montalban; L Vécsei; C Rajda; D Galimberti; E Scarpini; A Altintas; K Rejdak; J L Frederiksen; G Pihl-Jensen; Peh Jensen; M Khalil; M M Voortman; F Fazekas; A Saiz; D La Puma; M Vercammen; L Vanopdenbosch; Bmj Uitdehaag; J Killestein; C Bridel; C Teunissen
Journal:  Mult Scler       Date:  2019-05-08       Impact factor: 6.312

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.